Progression of Quality of Life in Patients with Plaque Psoriasis Who Achieved Three or More Years of Complete Skin Clearance with Guselkumab Treatment: a Post hoc Analysis of the VOYAGE 1 Clinical Trial

Abstract Introduction The interleukin-23p19 subunit inhibitor, guselkumab, has demonstrated improvements in clinical and patient-reported outcome (PRO) measures in patients with moderate-to-severe psoriasis. Understanding the relationship among clinical response, PRO measures and baseline characteri...

Full description

Saved in:
Bibliographic Details
Main Authors: Luis Puig (Author), Antonio Costanzo (Author), Elke M. G. J. de Jong (Author), Tiago Torres (Author), Richard B. Warren (Author), Robert Wapenaar (Author), Sven Wegner (Author), Patricia Gorecki (Author), Talia Gramiccia (Author), Maria Jazra (Author), Jozefien Buyze (Author), Curdin Conrad (Author)
Format: Book
Published: Adis, Springer Healthcare, 2024-08-01T00:00:00Z.
Subjects:
Online Access:Connect to this object online.
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

Connect to this object online.

3rd Floor Main Library

Holdings details from 3rd Floor Main Library
Call Number: A1234.567
Copy 1 Available